Daiichi Sankyo Appoints John Tsai, MD, as Global Head of R&D

Estimated Read Time: 3 minutes

Daiichi Sankyo has announced the appointment of John Tsai, MD, as its new Global Head of Research and Development, strengthening the company’s leadership team as it advances its global oncology and specialty medicine strategy.

In his new role, Dr. Tsai will oversee Daiichi Sankyo’s worldwide research and development organization, guiding innovation from early discovery through clinical development and regulatory approval.

Experienced Leader in Global Drug Development

Dr. Tsai brings extensive experience across pharmaceutical research, clinical development, and regulatory strategy. He joins Daiichi Sankyo from Bristol Myers Squibb, where he served in senior leadership roles overseeing immunology, cardiovascular, and oncology development programs.

His background includes leading global teams, advancing late-stage clinical assets, and supporting regulatory submissions across multiple therapeutic areas.

Supporting Daiichi Sankyo’s R&D Vision

The appointment reflects Daiichi Sankyo’s continued investment in research-driven innovation, particularly in oncology, where the company is expanding its pipeline of antibody-drug conjugates and other targeted therapies.

Company leadership emphasized that Dr. Tsai’s scientific expertise and global development experience will play a critical role in accelerating the delivery of transformative medicines to patients worldwide.

About Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with a strong legacy in cardiovascular medicine and a growing focus on oncology and specialty therapies. The company leverages advanced science and technology to discover, develop, and deliver innovative treatments addressing unmet medical needs.

Learn more about Daiichi Sankyo’s research and global initiatives on the official Daiichi Sankyo website.